Nadim Salomon is an Infectious Disease physician affiliated with Mount Sinai Beth Israel. OpenAlex indexes 50 publications with 1,469 citations (h-index 22).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10 Union Sq E
Suite 3f
New York, NY 100033314
Telephone
212-420-4006Registry record last updated 7 May 2019.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20251 payment
- ViiV Healthcare CompanyProgram year20242 payments
- ViiV Healthcare CompanyProgram year202313 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
51%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor24.2%Dovato55%Tivicay25%Isentress11%Juluca10%Part D<11 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor10.4%Descovy71%Triumeq29%Part D<11 patients+ 4 more classes in this area
Cardiovascular
27.2%Statin15.8%Atorvastatin Calcium69%Rosuvastatin Calcium23%Pravastatin Sodium8%Part D<11 patientsCalcium channel blocker6.6%Amlodipine Besylate61%Nifedipine Er39%Part D<11 patients+ 4 more classes in this area
Nervous system
9%SSRI2.1%Escitalopram Oxalate56%Citalopram Hbr44%Part D<11 patientsBenzodiazepine1.8%Clonazepam50%Temazepam50%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 267. Delayed Pulmonary Tuberculosis (PTB) Diagnosis During the COVID-19 Pandemic: A Case Series
Open Forum Infectious Diseases
2022 - Pulmonary Cavitary Tuberculosis in a Patient with SARS-CoV-2 Pneumonia
Journal of Scientific Innovation in Medicine
2021 - Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial
The Journal of Infectious Diseases
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Ramesh Gowda, MD
Mount Sinai Beth Israel
Michael Serby, MD
Mount Sinai Beth Israel
Albert Min, MD
Mount Sinai Beth Israel
Maryna Skliut, MD
Mount Sinai Beth Israel
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”